Our Team
Professor Leila Roushangar (CEO)
Responsible for creating, planning, research, implementing and integrating the strategic direction of SynDerm the company 's technological plans and overseeing data security.
Associated Professor Marziyeh Aghazadeh (CTO)
Responsible for the management of research and development (R&D), the company 's overseeing data security
Dr.Sara Soleimanirad (CFO)
Responsible for the financial affairs and investor attraction
Dr.Babak Roushangar(CMO)
Responsible for generating revenue by increasing sales through successful marketing for the organization, using market research , pricing, product marketing, communication and advertising
Mehdi Yazdi
Responsible for the management of research and development (R&D), the company 's overseeing data security
Our Goal
1-Identifying, supporting and giving rise to novel ideas in regenerative medicine
2-Making constructive collaboration with international scientific societies
3-Introducing safe, natural and efficient solutions for current medical challenges
4-we highlight emerging concepts in tissue regeneration and repair, and provide some perspectives on how to translate current knowledge into viable clinical approaches for treating patients with wound-healing problems
Our Mission
SynDerm Ltd. is an academic-based company enjoying professional scientists in the field of regenerative medicine, molecular biology, clinical wound management, pharmaceutical science, and tissue engineering. Novel ideas in RCTeb Ltd. Company begin their journey through hours of challenging sessions, multiple laboratory examinations, in vitro and in vivo clinical studies, and finally in case of eligibility, become safe and efficient medical products. Here is the place where engineering science and medicine cooperate in harmony.
Our Vision
SynDerm Ltd. has begun its activity in regenerative medicine since 2021. SynDerm Ltd. is ready to have international multidisciplinary collaboration with universities, start-up companies and scientific societies, world-wide with the aim of introducing novel regenerative medicine wound managment products and becoming one of the top 10th in wound care market by the next 10 years.
About us
Developing acellular dermal xenograft by a
Safe, time saving, and cost benefit protocol as a temporary wound dresser for promoting secondary intention in deep and complicated wounds in animal and human.
What we do for Healthy skin?
SynDerm: is an academic based tissue engineering company to reconstruct skin and mucosa.
Dermobor: is the brand name of an advanced wound care product of synDerm.
Mission: to develop effective and practical acellular xenografts for mucosa and skin regeneration as temporary wound dresser in animal an human.
Vision: to be a leader in the acellular skin xenograft industry in the global market to treat and regenerate animals and human dermal and mucosal tissues.
The main advantages of Dermobor are pointed as following
Lack of Antigenicity
Resistant to Infection
Cost effective
Widely Available
Durable and High Strength
Stable and Suturable
Durable and High Strength
Protection from Fluid Loss
Pain Reliever
Increase Rate of Re-epithelialization
Biocompatibility and non-immunogenicity
After physical and chemical decellularisation with our modified method, there was no visible cellular material histologically (H&E staining). To determine the effectiveness of cell removal and the number of remaining nuclei 6‐diamidino‐2‐phenylindole (DAPI) staining (Sigma‐Aldrich) was used. SEM also confirmed the elimination of cells from the submucosa of the sheep intestine after using of this multistep method.
Lack of immun…
References
van der Veen VC, van der Wal MB, van Leeuwen MC, et al. Biological background of dermal substitutes. Burns. 2010 May;36(3):305-21. Epub 2009 Nov 7. Also available: http://dx.doi.org/10.1016/j.burns.2009.07.012. PMID: 19897310.
Davison-Kotler E, Sharma V, Kang NV, et al. A universal classification system of skin substitutes inspired by factorial design. Tissue Eng Part B Rev. 2018 Aug;24(4):279-88. Epub 2018 Feb 12. Also available: http://dx.doi.org/10.1089/ten.TEB.2017.0477. PMID: 29336231.
van der Veen VC, Boekema BK, Ulrich MM, et al. New dermal substitutes. Wound Repair Regen. 2011 Sep;19 Suppl 1: s59-65. Also available: http://dx.doi.org/10.1111/j.1524-475X.2011.00713.x. PMID: 21793967.
Shahrokhi, Shahriar, Anna Arno, and Marc G. Jeschke. "The use of dermal substitutes in burn surgery: acute phase." Wound Repair and Regeneration 22.1 (2014): 14-22.
Ferdowsi Khosroshahi A, Soleimani Rad J, Kheirjou R, Roshangar B, Rashtbar M, Salehi R, Ranjkesh MR, Roshangar L. Adipose tissue-derived stem cells upon decellularized ovine small intestine submucosa for tissue regeneration: An optimization and comparison method. J Cell Physiol. 2020 Feb;235(2):1556-1567. doi: 10.1002/jcp.29074. Epub 2019 Aug 9. PMID: 31400002.
Taghavi H, Soleimani Rad J, Mehdipour A, FerdosiKhosroshahi A, Kheirjou R, Hasanpour M, Roshangar L. Effect of Mineral Pitch on the Proliferation of Human Adipose Derived Stem Cells on Acellular Scaffold. Adv Pharm Bull. 2020 Sep;10(4):623-629. doi: 10.34172/apb.2020.075. Epub 2020 Aug 9. PMID: 33072541; PMCID: PMC7539320.